title: A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma.
abstract: BACKGROUND
  We previously reported that preoperative chemolipiodolization of the whole liver is effective for reducing the incidence of postoperative recurrence and prolonging survival in patients with resectable hepatocellular carcinoma (HCC). The present randomized controlled trial was performed to evaluate the influence of preoperative transcatheter arterial chemoembolization (TACE) on survival after the resection of HCC.
  
  
  METHODS
  Operative results and long-term outcome were prospectively compared among 42 patients who received only selective TACE targeting the tumor (selective group), 39 patients who received TACE targeting the tumor plus chemolipiodolization of the whole liver (whole-liver group), and 43 patients without preoperative TACE or chemolipiodolization (control group).
  
  
  RESULTS
  There were no serious side effects of TACE or chemolipiodolization and the operative outcomes did not differ among the three groups. Even though preoperative TACE induced complete tumor necrosis, there were no significant differences in the pattern of intrahepatic recurrence or the time until recurrence among the three groups. There were also no significant differences in disease-free survival or overall survival among the three groups, even among patients with larger tumor size.
  
  
  CONCLUSIONS
  These results indicate that preoperative selective TACE and whole-liver chemolipiodolization plus TACE do not reduce the incidence of postoperative recurrence or prolong survival in patients with resectable HCC.
authors.affiliation: Department of Surgery, Kansai Medical University, 2-3-1 Shinmachi, Hirakata, Osaka 573-1191, Japan. kaibori@hirakata.kmu.ac.jp
authors.forename: Masaki
authors.initials: M
authors.lastname: Kaibori
authors.forename: Noboru
authors.initials: N
authors.lastname: Tanigawa
authors.forename: Shuji
authors.initials: S
authors.lastname: Kariya
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ikeda
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Nakahashi
authors.forename: Junko
authors.initials: J
authors.lastname: Hirohara
authors.forename: Chizu
authors.initials: C
authors.lastname: Koreeda
authors.forename: Toshihito
authors.initials: T
authors.lastname: Seki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sawada
authors.forename: Kazuichi
authors.initials: K
authors.lastname: Okazaki
authors.forename: A-Hon
authors.initials: AH
authors.lastname: Kwon
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy; D002404:Catheterization / Q000379:methods; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage; D004998:Ethiodized Oil / Q000008:administration & dosage*; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods; D006499:Hepatic Artery; D006801:Humans; D007269:Injections, Intra-Arterial / Q000379:methods; D008099:Liver / Q000098:blood supply / Q000473:pathology / Q000601:surgery; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D010043:Outcome and Process Assessment, Health Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011300:Preoperative Care / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015251:Epirubicin; D004998:Ethiodized Oil